CISPLATIN AND OTHER PLATINUM derivatives are front-line chemotherapeutic agents in the treatment of solid tumors, including ovarian, head and neck, and testicular germ cell tumors (1, 31) . However, a major dose-limiting effect of cisplatin is its propensity to cause acute kidney injury. Cisplatin's nephrotoxic effects have been modelled in vitro and in vivo. In vitro, cisplatin induces DNA damage (11, 27) , mitochondrial dysfunction (29) , formation of reactive oxygen species (16) , caspase activation (9) , and necrotic and apoptotic cell death (19) . In addition to these direct effects in vitro, in vivo studies showed significant injury to the renal microvasculature and a key role for leukocytes, including T cells, in cisplatin-induced nephrotoxicity. In particular, experimental in vivo studies defined a pathogenetic role for both CD4ϩ and CD8ϩ cells in cisplatin nephrotoxicity (13) .
The T cell immunoglobulin mucin (Tim) family consists of eight genes in mice (Tim1-8) and three in humans (TIM-1, -3, and -4) (4). Tim family members are cell surface glycoproteins sharing common motifs, including an IgV domain, a mucinlike domain, a transmembrane domain, and intracellular tail. Tim-1, expressed by activated T cells (4) , has the capacity to act as a costimulatory signal and may further activate T cells in a TCR-independent manner (15) . In injured kidneys, Tim-1 is expressed by tubular epithelial cells after ischemic or toxic injury (5, 8) and is known as kidney injury molecule-1 (Kim-1). The Kim-1 ectodomain is stable in urine, can be detected in the urine of humans with acute kidney injury, and is a potential biomarker (5) , and functionally, Kim-1 allows tubular cells to phagocytose apopotic debris via recognizing phosphatidylserine (7) .
Given that Tim-1 can activate T cells, the current studies were conducted to test the hypothesis that inhibiting Tim-1 would attenuate cisplatin-induced acute kidney injury. To achieve this, we used an antagonistic anti-Tim-1 antibody, RMT1-10, in studies involving wild-type (WT) C57BL/6 mice and in Rag1 Ϫ/Ϫ mice that lack adaptive immunity. This RMT1-10 antibody does not block the binding of apoptotic cells to Tim-1 (10) , or affect the more recently described Tim-1/LMIR5 interaction that assists neutrophil recruitment (35) , so there is no current evidence that this antibody affects tubular cell Kim-1 function. Our results showed that antiTim-1 treatment reduces functional and histological renal damage after cisplatin injection, provided the mice have an intact adaptive immune system, with significant alterations in T cell activation and cytokine production. This resulted in decreased renal leukocyte recruitment, proinflammatory cytokine and chemokine mRNA expression, NF-B activation, and reduced tubular cell apoptosis.
MATERIALS AND METHODS
Experimental design. Male mice were used for experiments. C57BL/6 mice were from Monash University Animal Services (Melbourne, Australia) and Rag1 Ϫ/Ϫ mice (C57BL/6 background) were bred at the Monash Medical Centre Specific Pathogen Free Facility. Studies were approved by Monash University's Animal Ethics Committee in accordance with the Australian National Health and Medical Research Council guidelines for animal experimentation. For experiments, mice were 8 -10 wk old (25-30 g ). Cisplatin (Sigma, St. Louis, MO) was freshly prepared in saline (1 mg/ml) and injected intraperitoneally at 20 mg/kg (for C57BL/6 mice) and 20 or 30 mg/kg (for Rag1 Ϫ/Ϫ experiments). The doses of cisplatin used in these experiments did not result in any mortality at either the day 1 or day 3 experimental timepoint.
An antagonistic anti-mouse Tim-1 monoclonal antibody (RMT1-10; rat IgG2a, 0.25 mg), specific for the IgV domain of Tim-1 and described previously (34) , or nonimmune rat IgG (prepared by protein G purification of rat serum) was injected intraperitoneally 3 h before and 24 h after cisplatin injection. Mice were humanely killed on day 1 (anti-Tim-1 n ϭ 4; rat IgG n ϭ 5) or day 3 (anti-Tim-1 n ϭ 8; rat IgG n ϭ 12). All animals in each group were studied for each endpoint. To assess the role of adaptive immunity, C57BL/6 WT mice (n ϭ 9) and Rag1 Ϫ/Ϫ mice (n ϭ 4) were injected with 20 mg/kg of cisplatin and assessed at day 3. To assess the role of Tim-1 independent of adaptive immunity, groups of Rag1 Ϫ/Ϫ mice were given anti-Tim-1 antibodies or rat IgG (0.25 mg ip) 3 h before and 24 h after cisplatin injection (30 mg/kg) and then humanely killed on day 3 (anti-Tim-1 n ϭ 6; rat IgG n ϭ 6). Given the contributions of T cells to this lesion (13), a higher dose of cisplatin (30 mg/kg), chosen according to preliminary experiments, was used so that a significant degree of injury occurred in the absence of T cells. Control mice were injected with the same volume of saline (n ϭ 4). Blood was collected from the dorsal aorta in heparinized tubes for serum urea, and TNF by ELISA, described previously (23) . Histological assessments were performed on coded slides on at least 10 high-power fields (hpf) per mouse and expressed as cells per 10 hpf (c/10hpf) (14) . Results are expressed as means Ϯ SE. Unpaired t-test was used for statistical analysis (GraphPad Prism; GraphPad Software, San Diego, CA). Differences were considered statistically significant if P Ͻ 0.05.
Assessment of renal injury. Tubular injury was assessed in formalin-fixed, paraffin-embedded 3-m periodic acid Schiff -stained sections using a semiquantitative scale (21) in which tubules in the outer medulla with cell necrosis, loss of brush border, cast formations, and tubule dilatation were scored: 0 ϭ normal; 1 ϭ Ͻ10% affected; 2 ϭ 10 -25%; 3 ϭ 26 -75%; 4 ϭ Ͼ75% affected. Macrophages, CD4ϩ and CD8ϩ cells were demonstrated by immunoperoxidase staining of periodate-lysine-paraformaldehyde-fixed frozen 6-m sections (32) . Neutrophils were assessed by immunoperoxidase staining using antigen retrieval (10- Immunohistochemical analysis of cleaved caspase-3 and phospho NF-B p65, Kim-1, and Tim-4. Cleaved caspase-3 and phospho NF-B p65 were identified in 4-m formalin-fixed kidney sections using rabbit anti-cleaved caspase-3 antibody or rabbit anti-phospho NF-B p65 antibody (both Cell Signaling Technology, Beverly, MA); the slides were treated with antigen retrieval (20 min), as described previously (14, 30) . Immunohistochemical staining for Kim-1 and Tim-4 was performed on 6-m periodate-lysine-paraformaldehydefixed kidney sections using a Vectastatin Elite ABC kit (Vector, Burlingame, CA). Endogenous peroxidase activity was ablated by incubation in 3% hydrogen peroxide (20 min) and sections were treated with avidin/biotin blocking solution (Vector) for 15 min. After incubation with the primary antibody, rat anti-Tim-1 monoclonal antibody (R&D Systems, Minneapolis, MN, 1 h) and rabbit antiTim-4 antibody (Lifespan Bioscience, Seattle, WA, overnight), biotinylated-conjugated secondary antibody, and biotin-rabbit anti-rat antibody or biotin-swine anti-rabbit antibody (Dako, Glostrup, Denmark) were applied (room temperature, 40 min), and then sections were incubated with the ABC kit (room temperature, 40 min) and color was developed with DAB (Sigma).
RT-PCR analyses. RNA was extracted from kidneys 3 days after cisplatin injection using TRIzol (Invitrogen Life Technologies, Mount Waverley, Australia). RT-PCR was performed on a Rotor Gene RG-3000 (Corbett Research, Mortlake, Australia) using FastStart DNA master Sybr Green I (Roche Diagnostics, Castle Hill, Australia) for intrarenal mRNA expression of IFN-␥, TNF, IL-1␤, IL-6, CCL2, CCL3, CCL5, CXCL1, CXCL2, CXCL9, CXCL10, ICAM-1, and 18SrRNA and RT-PCR for Tim-1, IL-4, IL-10, and 18SrRNA was performed using TaqMan predesigned real-time PCR assays (Applied Biosystems, Foster City, CA). Primer sequences are available on request. Results were standardized to the housekeeping gene 18S and expressed as fold differences relative to control animals not injected with cisplatin.
T cell activation, apoptosis, cytokine production, and Tregs. For assessment of activation, apoptosis, and proliferation by flow cytometry, spleens were obtained from mice on day 1 after cisplatin. Antibodies for flow cytometry were APC/Cy7-anti-CD4, APC-anti-CD8, FITC-anti-CD44, FITC-anti-CD25, FITC-anti-IL-17A, and PEanti-IFN-␥ (all BD Biosciences, North Ryde, Australia) and an antimouse foxp3 staining set (eBioscience). T cell activation was assessed by analysis of CD44 expression on splenic CD4ϩ cells (12) . T cell apoptosis was assessed by FITC-labeled annexin-V staining (Roche Diagnostics) with propidium iodide (1 g/ml; Calbiochem, San Diego, CA), as described previously (21) . Intracellular cytokine staining was performed on cells 1 day after cisplatin injection. Splenocytes were cultured with 50 ng/ml PMA and 750 ng/ml ionomycin for 4 h and then 10 g/ml brefeldin A (all Sigma). Cells were incubated with anti-CD4 and anti-CD8 antibodies, fixed, and permeabilized and then stained with anti-cytokine antibodies. For all markers, isotypematched irrelevant monoclonal antibodies were used as controls.
RESULTS
Anti-Tim-1 antibodies attenuate injury in cisplatin nephrotoxicity. One day after cisplatin injection, kidneys from control antibody (rat IgG)-treated mice showed some tubular dilation and a loss of brush border in the outer medulla (Fig. 1A) . By day 3, rat IgG-treated mice had developed severe tubular injury with cast formation, sloughing of tubular epithelial cells, tubular dilation, and significant injury with necrosis ( Fig. 1, C and E) . The anti-Tim-1 antibody (RMT1-10) protected kidneys from cisplatin nephrotoxicity. On day 1, renal morphology in anti-Tim-1 antibody-treated mice was normal, with preserved brush-border membranes and no tubular epithelial cell loss (Fig. 1B) . By day 3, although renal histology had become abnormal, less histological damage was present compared with cisplatin-injected, rat IgG-treated mice (Fig. 1D) . Formal semiquantitative injury scoring showed a trend toward a reduced necrosis score in anti-Tim-1 antibodytreated mice on day 1 (rat IgG 1.0 Ϯ 0.3, anti-Tim-1 0.3 Ϯ 0.3) and by day 3 (rat IgG 3.5 Ϯ 0.2, anti-Tim-1 2.3 Ϯ 0.5), mice were significantly protected (Fig. 1E) . Anti-Tim-1 antibodies protected mice from functional injury, as the cisplatin-induced rise in serum urea at day 3 (rat IgG 50.3 Ϯ 6.7, anti-Tim-1 30.1 Ϯ 3.2 mmol/l) was significantly less in anti-Tim-1 antibodytreated mice than in rat IgG-injected mice (Fig. 1F) .
Anti-Tim-1 antibodies limit renal leukocyte accumulation in cisplatin nephrotoxicity. Interstitial infiltrates of CD4ϩ cells ( Fig. 2A ) and CD8ϩ cells (Fig. 2B) peaked on day 1. These infiltrates were markedly diminished in mice given anti-Tim-1 antibody (CD4: rat IgG 93 Ϯ 14, anti-Tim-1 18 Ϯ 5; CD8: rat IgG 58 Ϯ 4 and anti-Tim-1 25 Ϯ 4 c/10 hpf). When overall numbers had declined by day 3, differences between groups were not significant. Tubulointerstitial neutrophil (Fig. 2C) and macrophage ( Fig. 2D) infiltrates followed a different time course, with the greatest increase in cisplatin-injected, rat IgG-treated mice at day 3. In anti-Tim-1 antibody-treated mice, neutrophil and macrophage numbers were not significantly reduced at day 1 (neutrophils: rat IgG 7 Ϯ 3, anti-Tim-1 4 Ϯ 2; macrophages: rat IgG 27 Ϯ 7, anti-Tim-1 14 Ϯ 6 c/10 hpf), but at day 3, the time of peak infiltrate in control-treated mice, renal neutrophil and macrophage numbers were reduced in anti-Tim-1 antibody-treated mice (neutrophils: rat IgG 56 Ϯ 8 and anti-Tim-1 16 Ϯ 3, macrophages; rIgG 52 Ϯ 2, anti-Tim-1 37 Ϯ 4 c/10 hpf).
Anti-Tim-1 antibodies inhibit cisplatin-induced NF-B activation and apoptosis. Intrarenal NF-B activation is a feature of cisplatin nephrotoxicity (30) . There was a progressive increase in tubular cells positive for phospho NF-B p65, a marker of NF-B activation, in cisplatin-injected, rat IgGtreated mice. Anti-Tim-1 antibodies resulted in fewer cells expressing phospho NF-B p65, at both time points (day 1: rat IgG 1.2 Ϯ 0.1, anti-Tim-1 0.2 Ϯ 0.2 c/10 hpf; day 3: rat IgG 29.9 Ϯ 4.9, anti-Tim-1 13.1 Ϯ 3.9 c/10 hpf; Fig. 3, A-C) . Apoptosis represents a key event after cisplatin injection, correlating with the degree of injury (17) . Cells expressing cleaved caspase-3, a marker of apoptosis, were not present at day 1 but by day 3 were present in cisplatin-injected, rat IgG-treated mice, but significantly reduced in mice treated with anti-Tim-1 antibodies (rat IgG 15.3 Ϯ 3.1, anti-Tim-1 5.4 Ϯ 2.2 c/10 hpf; Fig. 3, D-F) .
Tim-1 and Tim-4 expression in the kidney after cisplatin treatment. Tim-1 (also known as Kim-1) indicates renal injury. By day 1, Tim-1 was present in the proximal tubules in the apical region of outer medulla (Fig. 4, A and B) . On day 3, Tim-1 immunostaining was present in the apical part of many of the proximal tubular cells with more diffuse cytoplasmic staining in the outer medulla (Fig. 4, C and D) . (Fig. 5, A-C) . The relative decrease in Tim-4 was similar to that observed in macrophage numbers in Fig. 2D .
Inhibiting Tim-1 attenuates cisplatin-induced intrarenal inflammatory mediators. The expression of several cytokines and chemokines is increased in kidneys in cisplatin nephrotoxicity and contributes to renal injury (23) (24) (25) . Intrarenal mRNA expression of TNF, a cytokine with a pathogenic role in cisplatin nephrotoxicity (24) , was decreased (rat IgG 5.8 Ϯ 1.2, anti-Tim-1 2.1 Ϯ 0.5-fold increase over baseline; Fig. 6A ). This reduction within the kidney was not due to changes in serum TNF levels after anti-Tim-1 treatment. Serum TNF on day 1 was not detected in any mouse (limit of ELISA's Fig. 2 . Tim-1 mediates interstitial leukocyte accumulation in the outer medulla after cisplatin injection. Numbers of CD4ϩ (A) and CD8ϩ (B) T cells peaked at day 1 and were reduced in anti-Tim-1 antibody-treated mice compared with rat IgG-treated mice (c/10 hpf, cells per 10 high-power fields). Neutrophil (C) and macrophage (D) infiltrates were higher at day 3 but compared with rat IgG-injected mice, anti-Tim-1-treated mice had reduced neutrophils and macrophages. Dotted lines represent mean values from saline-injected mice without cisplatin. *P Ͻ 0.05 and **P Ͻ 0.01 vs. cell numbers in rat IgG-treated mice on the same day. †P Ͻ 0.05 vs. cell numbers in rat IgG-and anti-Tim-1 antibody-treated mice on day 1, and ¶P Ͻ 0.05 for CD4ϩ cells vs. both groups of mice on day 3; means Ϯ SE, unpaired t-test. (Fig. 6, B-D) , but the protective cytokine IL-10 was not reduced (rat IgG 2.1 Ϯ 0.6, anti-Tim-1 3.9 Ϯ 2.1; Fig. 6E ). Anti-Tim-1 antibodies limited the increase in several chemokines, including, in particular, neutrophil and T cell chemoattractants (Fig. 7, A and  B) . In addition, the increase in mRNA for ICAM-1, an adhesion molecule important in leukocyte recruitment, was attenuated by anti-Tim-1 antibodies (rat IgG 4.3 Ϯ 0.7, anti-Tim-1 2.5 Ϯ 0.5; Fig. 7C) .
T cell activation and IFN-␥ production are reduced by anti-Tim-1 antibodies. Activation, apoptosis, and cytokine production on splenic CD4ϩ and CD8ϩ T cells 24 h after cisplatin with or without anti-Tim-1 antibody treatment were examined by flow cytometric analysis (Fig. 8 ). CD4ϩ and CD8ϩ T cell activation (CD44) (CD4: rat IgG 7.9 Ϯ 0. 
C-D:
on day 3, Kim-1 is detected in many tubules in the injured outer medulla, localized to the apical side of the epithelium with some diffuse cytoplasmic staining. Anti-Tim-1 antibody-treated mice showed fewer Kim-1ϩ tubules than rat IgG-injected mice (high power ϫ400). E: Kim-1 renal mRNA expression in anti-Tim-1 antibody-treated mice was reduced compared with that in rat IgGtreated mice. *P Ͻ 0.05 vs. rat IgG-treated mice on day 3. †P Ͻ 0.05 vs. rat IgG-treated mice on day 1; means Ϯ SE, unpaired t-test. and anti-Tim-1 1.7 Ϯ 0.3%) were diminished in anti-Tim-1 antibody-treated mice. Anti-Tim-1 treatment reduced the frequency of IFN-␥ producing CD4ϩ and CD8ϩ T cells (CD4: rat IgG 4.1 Ϯ 0.3, anti-Tim-1 2.8 Ϯ 0.5; CD8: rat IgG 22.4 Ϯ 3.2, anti-Tim-1 9.1 Ϯ 2.1%), but proportions of IL-17A-producing cells were unchanged (CD4: rIgG 1.6 Ϯ 0.2, antiTim-1 1.7 Ϯ 0.1; CD8: rat IgG 1.1 Ϯ 0.2, anti-Tim-1 1.6 Ϯ 0.2%). There were no differences in proportions of regulatory cells (CD25ϩfoxp3ϩCD4ϩ) between the two groups (rat IgG 2.3 Ϯ 0.2 vs. anti-Tim-1 2.1 Ϯ 0.1% of CD4ϩ cells).
Renal injury in Rag1
Ϫ/Ϫ mice is not modified by anti-Tim-1 antibodies. Tim-1 had significant effects on T cells that are important in this model of injury (13) . At the dose of cisplatin (20 mg/kg) used in these studies, we confirmed that injury was substantially dependent on adaptive immunity by injecting cisplatin into WT C57BL/6 and Rag1 Ϫ/Ϫ mice. Rag1 Ϫ/Ϫ mice are deficient in recombination-activating gene-1, critical in V(D)J recombination in lymphocytes, and therefore lack mature T and B cells. Rag1 Ϫ/Ϫ mice were protected from renal impairment after 3 days (serum urea: WT 60.2 Ϯ 5.6 vs.
Rag1
Ϫ/Ϫ 8.1 Ϯ 7.3 mmol/l and necrosis score: 3.8 Ϯ 0.3 vs. 1.1 Ϯ 0.2; P Ͻ 0.01). Therefore, we induced cisplatin nephrotoxicity in Rag1 Ϫ/Ϫ mice to determine whether anti-Tim-1 antibodies had any effect in the absence of T cells, so that effects on T cells could be separated from any potential local effects on renal tubular cell Tim-1 (Kim-1). To ensure that we induced easily measurable injury in Rag1 Ϫ/Ϫ mice, a higher dose of cisplatin (30 mg/kg) was used. Anti-Tim-1 antibody treatment had no effect on either the structural manifestations of cisplatin nephrotoxicity or renal impairment (Fig. 9 ).
DISCUSSION
While cisplatin nephrotoxicity is associated with oxidative stress, DNA damage, apoptosis, and necrosis (20) , there is an important role for inflammation in the pathogenesis of both toxic and ischemic acute kidney injury (26, 36) . In response to ischemic or toxic insults, the kidney upregulates the expression of a number of cytokines, chemokines, and adhesion molecules (23) (24) (25) , and leukocyte populations, including neutrophils (22, 36) , T cells (2, 13, 22) , and macrophages (36) , are increased and/or activated. Moreover, inhibiting some chemokines, cytokines, or adhesion molecules (25, 29) ameliorates experimental acute kidney injury.
The current studies demonstrate that 1) anti-Tim-1 antibodies significantly reduce cisplatin nephrotoxicity, 2) anti-Tim-1 antibodies affect early immune responses, including activation, apoptosis, and cytokine production on CD4ϩ and CD8ϩ T-cells, 3) anti-Tim-1 antibodies ameliorate the cisplatin-induced upregulation of proinflammatory cytokines, chemokines, and ICAM-1 expression, resulting in decreased infiltration of leukocytes into kidney, with less NF-B activation and less apoptosis, and 4) the protection from cisplatin nephrotoxicity is mediated predominantly through cells of the adaptive immune system, most likely T cells.
T cells, probably acting innately, can direct inflammatory injury in cisplatin nephrotoxicity and other forms of acute kidney injury (2, 13, 22) , evidence supported by the current studies. More importantly, when considering the role of Tim-1, the current studies showed that anti-Tim antibodies could modify the T cell inflammatory phenotype at an early stage. Recent evidence suggested that Tim-1 can bypass the TCR to further activate T cells (15) , and it is likely that this effect is important in the current studies. No protection was afforded by anti-Tim-1 antibodies in Rag1 Ϫ/Ϫ mice, showing that Tim-1's effects on CD4ϩ cells (and potentially CD8ϩ cells) promote cisplatin nephrotoxicity.
Different anti-Tim-1 antibodies have different effects on Tim-1. A high-affinity anti-Tim-1 antibody (3B3) enhances the expansion, activation, and survival of T cells with increased IFN-␥ and IL-17A production, whereas the low-affinity antibody used in the current studies (RMT1-10) has inhibitory effects in the same system (34) . It is likely that these key effects on reducing T cell activation are played out in the reduced downstream inflammatory events seen within the kidney itself. T cells are well-known to activate macrophages, and, in addition to the current studies, evidence from Tim-1 inhibition in hepatic ischemia-reperfusion injury suggests that T cell-dependent macrophage activation is interrupted by antiTim-1 antibodies (33) . These studies also show less apoptosis and hepatocellular damage after RMT1-10 administration (33) . It is possible that T cell Tim-1/macrophage Tim-4 interactions within the kidney contribute to cisplatin nephrotoxicity, as Tim-1 can affect macrophage activation (6) . In the interstitium, there were fewer Tim-4ϩ cells, consistent with the diminished macrophage influx after Tim-1 inhibition.
There are other potential mechanisms by which Tim-1 may participate in cisplatin nephrotoxicity, most of which, in the context of our studies, can be effectively discounted given the nature of the anti-Tim-1 RMT1-10 antibody and our use of Rag1 Ϫ/Ϫ mice. Intrarenal Kim-1 plays a central role in the removal of dead cells and other debris from the tubular lumen with Kim-1-expressing epithelial cells having highly phagocytic properties in vivo (14) . It is likely that Tim-1 acts locally, either on damaged tubular cells or on infiltrating leukocytes, as a phosphatidylserine receptor to mediate clearance of apoptotic cells. However, in the current studies, the effects of Tim-1 inhibition are unlikely to be directly related to local Tim-1 (Kim-1) effects, as Rag1 Ϫ/Ϫ mice were not protected by anti-Tim-1 antibodies, and the RMT1-10 antibody does not inhibit Tim-1 binding to apoptotic cells (10) . Tim-1-dependent NKT cell activation is also mediated through binding of apoptotic cells (10) . While it is impossible to exclude effects on B cells (as we used Rag1 Ϫ/Ϫ mice) and Tim-1 is present in some B cells at low levels (28) , studies using nude mice, CD4Ϫ/Ϫ Fig. 9 . Effects of anti-Tim-1 antibodies on histological evaluation (A and B: photomicrographs in the outer medulla; C: scoring of injury) and serum urea (D) in Rag1 Ϫ/Ϫ mice 3 days after acute kidney injury induced by 30 mg/kg of cisplatin. Both serum urea and histological injury were similar in the 2 groups. High power ϫ400. Dotted lines represent mean values from saline-treated mice without cisplatin. Data are means Ϯ SE. Fig. 8 . Anti-Tim-1 antibodies limit early CD4ϩ and CD8ϩ T cell responses. One day after injection of cisplatin, splenic CD4 (A) and CD8 (B) T cell activation, apoptosis, and cytokine production were assessed by flow cytometric analysis of CD44 expression, annexin-V binding, and intracellular IFN-␥ and IL-17A production. CD4ϩ and CD8ϩ cell activation, apoptosis, and IFN-␥ production were reduced by anti-Tim-1 antibodies. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001 vs. rat IgG-treated mice; means Ϯ SE, unpaired t-test. and CD8Ϫ/Ϫ mice, showed a key role for T cells in cisplatin nephrotoxicity (2, 22) .
In conclusion, in cisplatin nephrotoxicity, Tim-1 signaling helps activate T cells, which mediate acute kidney injury. Inhibiting Tim-1 ameliorates acute kidney injury by inhibiting T cell activation, thereby inhibiting leukocyte recruitment and inflammatory injury. The current studies define a new mechanism by which Tim-1 signaling affects T cell-directed proinflammatory cascades in acute kidney injury.
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